DE60042369D1 - Chemisch programmierbare immunität - Google Patents

Chemisch programmierbare immunität

Info

Publication number
DE60042369D1
DE60042369D1 DE60042369T DE60042369T DE60042369D1 DE 60042369 D1 DE60042369 D1 DE 60042369D1 DE 60042369 T DE60042369 T DE 60042369T DE 60042369 T DE60042369 T DE 60042369T DE 60042369 D1 DE60042369 D1 DE 60042369D1
Authority
DE
Germany
Prior art keywords
molecule
binding site
chemical
immunity
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042369T
Other languages
English (en)
Inventor
Kary B Mullis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altermune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60042369D1 publication Critical patent/DE60042369D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Residential Or Office Buildings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE60042369T 1999-12-22 2000-12-21 Chemisch programmierbare immunität Expired - Lifetime DE60042369D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17170799P 1999-12-22 1999-12-22
PCT/US2000/035179 WO2001045734A1 (en) 1999-12-22 2000-12-21 Chemically-programmable immunity

Publications (1)

Publication Number Publication Date
DE60042369D1 true DE60042369D1 (de) 2009-07-23

Family

ID=22624828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042369T Expired - Lifetime DE60042369D1 (de) 1999-12-22 2000-12-21 Chemisch programmierbare immunität

Country Status (9)

Country Link
US (5) US20030017165A1 (de)
EP (1) EP1242115B1 (de)
AT (1) ATE433327T1 (de)
AU (1) AU3076601A (de)
CA (1) CA2328356A1 (de)
DE (1) DE60042369D1 (de)
DK (1) DK1242115T3 (de)
ES (1) ES2328102T3 (de)
WO (1) WO2001045734A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
EP2230249A3 (de) * 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/Antikörper oder Ligand/Rezeptor glycosylierter Spezifität Austauscher
US7440877B2 (en) * 2004-03-12 2008-10-21 General Motors Corporation System and method for morphable model design space definition
US20070134259A1 (en) * 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy
EP1790358A1 (de) 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
CA2681766A1 (en) * 2007-03-23 2008-10-02 The Governors Of The University Of Alberta Multivalent heterobifunctional polymers and methods of their use
WO2010129666A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45468A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques myc et utilisations
MA45471A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
EP3565577A4 (de) 2017-01-06 2020-10-07 Avidity Biosciences, Inc. Nukleinsäure-polypeptidzusammensetzungen und verfahren zur induktion von exon-skipping
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
MA51103A (fr) 2017-12-06 2020-10-14 Avidity Biosciences Inc Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
EP3898693A4 (de) 2018-12-21 2022-09-21 Avidity Biosciences, Inc. Anti-transferrin-rezeptor-antikörper und verwendungen davon
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
AU2020289464A1 (en) 2019-06-06 2022-01-20 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
JP2023527638A (ja) 2020-03-27 2023-06-30 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169137A (en) * 1974-12-20 1979-09-25 Block Engineering, Inc. Antigen detecting reagents
IL51667A (en) * 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4737453A (en) * 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
US4637459A (en) * 1985-06-28 1987-01-20 Roussel Louis J Anti rotational device for down hole hydraulic pumping unit
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5218088A (en) * 1989-11-02 1993-06-08 Purdue Research Foundation Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
US6331394B1 (en) * 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6261774B1 (en) * 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
DK0533838T3 (da) * 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
AU9053991A (en) 1990-11-20 1992-06-11 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
WO1995005454A1 (en) 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP0833666B1 (de) * 1996-04-10 2003-12-10 Sangstat Medical Corporation Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
DE69840723D1 (de) * 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US7112328B2 (en) * 1998-07-16 2006-09-26 Vincent Marinkovich Composition for targeted cell treatment
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
EP1088889A1 (de) 1999-10-01 2001-04-04 University Of Cambridge Rekombinanter doppelt-hybrider filamentöser Bakteriophage
EP1964854A2 (de) 1999-10-27 2008-09-03 Cel-Sci Corporation Verfahren zur Herstellung und Zusammensetzung von Peptid-Konstrukten zur Behandlung von Wirt versus Transplantat-bedingten Autoimmun- und Transplantatbedingungen
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
PL211872B1 (pl) * 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs

Also Published As

Publication number Publication date
US7850975B2 (en) 2010-12-14
US20120276136A1 (en) 2012-11-01
US7422746B2 (en) 2008-09-09
ES2328102T3 (es) 2009-11-10
US20070148183A1 (en) 2007-06-28
US20090142368A1 (en) 2009-06-04
AU3076601A (en) 2001-07-03
EP1242115A4 (de) 2004-06-16
US8236321B2 (en) 2012-08-07
WO2001045734A1 (en) 2001-06-28
US8591910B2 (en) 2013-11-26
CA2328356A1 (en) 2001-06-22
DK1242115T3 (da) 2009-10-05
ATE433327T1 (de) 2009-06-15
US20040146515A1 (en) 2004-07-29
EP1242115A1 (de) 2002-09-25
US20030017165A1 (en) 2003-01-23
EP1242115B1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
DE60042369D1 (de) Chemisch programmierbare immunität
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DK1200418T3 (da) Nematodicide trifluorbutener
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BG64475B1 (bg) Ципразидонови соли
DK1237584T3 (da) Receptorbindende konjugater
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
AU2002364954A1 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
DE60033649D1 (de) Verbindungen und therapeutische methoden
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
DK1684770T3 (da) Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
SE0003476D0 (sv) Compounds
GB9921592D0 (en) Preparation of highly pure toxin fragments
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALTERMUNE, LLC, CORONA DEL MAR, CALIF., US

8364 No opposition during term of opposition